NASDAQ · ZVRA
Zevra Therapeutics, Inc.
$10.21-$0.15 (-1.45%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.2% below the high.
Loading market information…
NASDAQ · VACC · USD
Stock price, earnings
Quote as of Nov 6, 2023, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Vaccitech plc’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vaccitech plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vaccitech plc is a clinical-stage biopharmaceutical company focused on developing cutting-edge T-cell immunotherapeutics and vaccines. Their mission is to treat and prevent a variety of infectious diseases and cancers. The company's therapeutic pipeline includes several programs undergoing clinical evaluation: VTP-300 is in Phase 1/2a clinical trials for chronic hepatitis B. VTP-200 is also in Phase 1/2a development, targeting human papillomavirus (HPV) infection. VTP-850 is progressing through Phase 1/2 clinical studies for prostate cancer. VTP-600 is engaged in Phase 1/2a trials for non-small cell lung cancer. In terms of prevention, their prophylactic initiatives feature: VTP-400, which is in a preclinical stage, designed to combat herpes zoster (shingles). VTP-500, which has concluded Phase 1 clinical trials for Middle East respiratory syndrome (MERS). Notably, Vaxzevria, a preventive vaccine against COVID-19 infection, is also part of their offerings. Established in 2016, the company was originally named Vaccitech Rx Limited before adopting its current name, Vaccitech plc, in March 2021. Vaccitech plc is headquartered in Oxford, United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2022 |
|---|
| Nov 10, 2022 |
| $0.22+166.67% vs estimate |
| $6.17M+86.25% vs estimate |
KEEP COMPARING
$10.21-$0.15 (-1.45%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.2% below the high.
$2.27$0.00 (0.0%)
Acelyrin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$4.47$0.00 (0.0%)
CARGO Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 82.44% below the high.
$1.03-$0.01 (-0.49%)
Spectrum Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.71% below the high.
$4.07+$0.01 (+0.12%)
Theseus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.14% below the high.
$7.12$0.00 (0.0%)
F-star Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.88-$0.08 (-8.0%)
Selecta Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.72% below the high.
$3.33-$0.17 (-4.73%)
LENZ Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.65% below the high.
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
